CervoMed Inc.
CervoMed Inc. (Nasdaq: CRVO) is a clinical-stage biotechnology company developing treatments for age-related brain disorders. Its lead investigational drug candidate, neflamapimod, is an orally administered small molecule designed to cross the blood-brain barrier and inhibit p38α, and is being studied for dementia… From the company’s description.
Over the twelve months to Sep 30, 2026, CervoMed Inc. reported revenue of $0.01M, down 99.9% from a year earlier, and a net loss of $28.52M. Operations used $26.59M in cash. In fiscal 2025, it reported revenue of $4.01M, down 58.9% from fiscal 2024, and a net loss of $26.97M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What CervoMed Inc. does
In the company’s own words
CervoMed Inc. (Nasdaq: CRVO) is a clinical-stage biotechnology company developing treatments for age-related brain disorders. Its lead investigational drug candidate, neflamapimod, is an orally administered small molecule designed to cross the blood-brain barrier and inhibit p38α, and is being studied for dementia with Lewy bodies (DLB), nonfluent variant primary progressive aphasia, recovery after stroke, and amyotrophic lateral sclerosis. The company’s DLB program focuses on patients without Alzheimer’s disease co-pathology; its planned Phase 3 trial is designed to assess neflamapimod against placebo. CervoMed has also initiated Phase 2a trials in primary progressive aphasia and stroke recovery, and neflamapimod has been selected for a platform trial in ALS. The company’s business centers on research and development of neflamapimod rather than reportable operating segments or marketed products. CervoMed was formed through the August 2023 merger of Diffusion Pharmaceuticals and EIP Pharma, with EIP Pharma as the accounting acquirer. Its website is https://www.cervomed.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- BOSTON, MA
- Fiscal year end
- December
- CIK
- 1053691
- SIC
- 2834
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns CervoMed Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · CervoMed Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do CervoMed Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of CervoMed Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in CervoMed Inc.'s last four quarterly filings that the numbers alone won't show?”